M E Erwin

1.1k total citations
44 papers, 926 citations indexed

About

M E Erwin is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, M E Erwin has authored 44 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pharmacology, 23 papers in Molecular Medicine and 16 papers in Epidemiology. Recurrent topics in M E Erwin's work include Antibiotics Pharmacokinetics and Efficacy (25 papers), Antibiotic Resistance in Bacteria (23 papers) and Antimicrobial Resistance in Staphylococcus (12 papers). M E Erwin is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (25 papers), Antibiotic Resistance in Bacteria (23 papers) and Antimicrobial Resistance in Staphylococcus (12 papers). M E Erwin collaborates with scholars based in United States, Brazil and Ireland. M E Erwin's co-authors include Ronald N. Jones, David M. Johnson, M S Barrett, Michael A. Pfaller, Douglas J. Biedenbach, Ana Espinel‐Ingroff, Henry M. Blumberg, Wendy Baughman, Monica M. Farley and Anne Schuchat and has published in prestigious journals such as Journal of Clinical Microbiology, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

M E Erwin

44 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M E Erwin United States	15	454	355	303	279	198	44	926
F. W. Goldstein France	15	382 0.8×	398 1.1×	277 0.9×	218 0.8×	104 0.5×	21	972
Michael A. Pfaller United States	18	389 0.9×	471 1.3×	299 1.0×	211 0.8×	205 1.0×	27	1.0k
Carmen Betriú Spain	20	406 0.9×	451 1.3×	323 1.1×	259 0.9×	334 1.7×	55	1.1k
Meridith E. Erwin United States	15	293 0.6×	376 1.1×	398 1.3×	370 1.3×	108 0.5×	44	887
Helen T. Fernandez United States	19	242 0.5×	417 1.2×	141 0.5×	170 0.6×	208 1.1×	26	865
L. J. Chalkley South Africa	19	477 1.1×	343 1.0×	230 0.8×	149 0.5×	158 0.8×	31	841
Joyce C. de Azavedo Canada	10	861 1.9×	427 1.2×	342 1.1×	454 1.6×	141 0.7×	11	1.2k
Matthew G. Stilwell United States	15	270 0.6×	457 1.3×	401 1.3×	334 1.2×	186 0.9×	20	1.0k
Deborah Ashcraft United States	16	223 0.5×	379 1.1×	364 1.2×	257 0.9×	150 0.8×	30	915
A Buré France	14	312 0.7×	270 0.8×	433 1.4×	249 0.9×	99 0.5×	45	884

Countries citing papers authored by M E Erwin

Since Specialization

Citations

This map shows the geographic impact of M E Erwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M E Erwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M E Erwin more than expected).

Fields of papers citing papers by M E Erwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M E Erwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M E Erwin. The network helps show where M E Erwin may publish in the future.

Co-authorship network of co-authors of M E Erwin

This figure shows the co-authorship network connecting the top 25 collaborators of M E Erwin. A scholar is included among the top collaborators of M E Erwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M E Erwin. M E Erwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Erwin, M E, et al.. (1999). Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. Diagnostic Microbiology and Infectious Disease. 34(2). 99–102. 12 indexed citations

Jones, Ronald N., Kari C. Kugler, M E Erwin, et al.. (1999). Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods. Diagnostic Microbiology and Infectious Disease. 33(4). 247–253. 8 indexed citations

Jones, Ronald N., Steven A. Marshall, & M E Erwin. (1999). Antimicrobial activity and spectrum of SCH27899 (ziracin®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Diagnostic Microbiology and Infectious Disease. 34(2). 103–110. 18 indexed citations

Johnson, David M., Ronald N. Jones, & M E Erwin. (1999). Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagnostic Microbiology and Infectious Disease. 33(2). 87–91. 42 indexed citations

Jones, Ronald N., David M. Johnson, M E Erwin, et al.. (1999). Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Diagnostic Microbiology and Infectious Disease. 34(2). 91–98. 15 indexed citations

Jones, Ronald N., M E Erwin, Douglas J. Biedenbach, David M. Johnson, & Michael A. Pfaller. (1999). Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. Diagnostic Microbiology and Infectious Disease. 35(3). 227–234. 4 indexed citations

Jones, Ronald N., et al.. (1997). Avaliação da sensibilidade a antimicrobianos de 87 amostras clínicas de enterococos resistentes à vancomicina. Revista da Associação Médica Brasileira. 43(3). 217–22. 5 indexed citations

Cormican, Martin, M E Erwin, & Ronald N. Jones. (1997). Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. Diagnostic Microbiology and Infectious Disease. 29(4). 241–248. 10 indexed citations

Cormican, Martin, M E Erwin, Steven A. Marshall, & Ronald N. Jones. (1996). Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagnostic Microbiology and Infectious Disease. 24(3). 155–160. 9 indexed citations

10.

Jones, Ronald N., et al.. (1995). Resistance among Important Pathogens and the Antimicrobial Activity of Parenteral Fluoroquinolones at 43 US Medical Centres. Drugs. 49(Supplement 2). 179–181. 3 indexed citations

11.

Jones, Ronald N., Gary V. Doern, E. Gerlach, Janet Hindler, & M E Erwin. (1994). Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. Diagnostic Microbiology and Infectious Disease. 18(4). 243–249. 9 indexed citations

12.

Jones, Ronald N., Hélio S. Sader, & M E Erwin. (1994). Update of lomefloxacin in vitro activity and spectrum. Diagnostic Microbiology and Infectious Disease. 20(2). 93–98. 2 indexed citations

13.

Erwin, M E, et al.. (1994). Evaluation of the etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis. Diagnostic Microbiology and Infectious Disease. 20(4). 213–219. 11 indexed citations

14.

Barrett, M S, Ronald N. Jones, & M E Erwin. (1993). In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds. European Journal of Clinical Microbiology & Infectious Diseases. 12(2). 134–141. 6 indexed citations

15.

Sader, Hélio S., M E Erwin, & Ronald N. Jones. (1992). In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. European Journal of Clinical Microbiology & Infectious Diseases. 11(4). 372–381. 30 indexed citations

16.

Johnson, David M., et al.. (1992). Antimicrobial activity of ten macrolide, linsosamine and streptogramin drugs tested againstLegionella species. European Journal of Clinical Microbiology & Infectious Diseases. 11(8). 751–755. 36 indexed citations

17.

Jones, Ronald N., David M. Johnson, M S Barrett, & M E Erwin. (1991). Antimicrobial Activity of Isepamicin (SCH21420, 1-N-HAPA Gentamicin B) Combinations with Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Imipenem, Mezlocillin and Piperacillin Tested Against Gentamicin-Resistant and Susceptible Gram-Negative Bacilli and Enterococci. Journal of Chemotherapy. 3(5). 289–294. 10 indexed citations

18.

Murray, Patrick R., S D Allen, M E Erwin, et al.. (1991). Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates. European Journal of Clinical Microbiology & Infectious Diseases. 10(9). 776–781. 3 indexed citations

19.

Washington, John A., Ronald N. Jones, S D Allen, et al.. (1991). In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates. Antimicrobial Agents and Chemotherapy. 35(7). 1508–1511. 7 indexed citations

20.

Jones, Ronald N., M E Erwin, & M S Barrett. (1990). In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination againstLegionella species. European Journal of Clinical Microbiology & Infectious Diseases. 9(11). 846–848. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact